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The neurotransmitter glutamate facilitates neuronal signalling at excitatory synapses. Glutamate is released from the
presynaptic membrane into the synaptic cleft. Across the synaptic cleft glutamate binds to both ion channels and
metabotropic glutamate receptors at the postsynapse, which expedite downstream signalling in the neuron. The
postsynaptic density, a highly specialized matrix, which is attached to the postsynaptic membrane, controls this
downstream signalling. The postsynaptic density also resets the synapse after each synaptic firing. It is composed of
numerous proteins including a family of Discs large associated protein 1, 2, 3 and 4 (DLGAP1-4) that act as scaffold
proteins in the postsynaptic density. They link the glutamate receptors in the postsynaptic membrane to other
glutamate receptors, to signalling proteins and to components of the cytoskeleton. With the central localisation in the
postsynapse, the DLGAP family seems to play a vital role in synaptic scaling by regulating the turnover of both
ionotropic and metabotropic glutamate receptors in response to synaptic activity. DLGAP family has been directly
linked to a variety of psychological and neurological disorders. In this review we focus on the direct and indirect role of
DLGAP family on schizophrenia as well as other brain diseases.
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The postsynaptic density (PSD) is a highly specialized
matrix that is involved in transmission of neuronal signals
across the synaptic junction. The PSD is found in the syn-
aptic terminal of postsynaptic neurons. A variety of proteins
is expressed in the PSD for transmitting neuronal signals
from the PSD to the soma or other parts of the neuron.
The PSD scaffolding proteins, Discs large scaffold proteins
(DLGs) and the family of Src-homology (SH3) and multiple
ankyrin repeat domain proteins (SHANK) are essential for
proper function of both the ionotropic N-methyl-D-aspar-
tate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazo-
lepropionic acid (AMPA) receptors and the metabotropic
glutamate receptors (mGluRs) [1–4]. The family of Discs
large associated proteins (DLGAPs) are also important scaf-
fold proteins in the PSD. There are five DLGAP proteins,
DLGAP1 – DLGAP5 where DLGAP1 - DLGAP4
(DLGAP1–4) proteins interact directly with both DLG and
SHANK through their multiple domains [2, 5, 6]. Via* Correspondence: asli@sund.ku.dk
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a role in multiple processes of the PSD. For example,
neuronal DLGAP proteins have key roles in synaptic scaling
[7, 8]. DLGAP1–4 proteins have also been linked to a
variety of neurological disorders including schizophrenia,
autism spectrum disease (ASD), trichotillomania, obsessive
compulsive disorder (OCD) and cerebellar ataxia [9–14]
(see Table 1). Here we present the existing knowledge on
the expression, function and the regulation of DLGAP1–4
in the brain. We also review the link of DLGAP1–4 to the
various neurological disorders. DLGAP5 is not included in
this review since it is mainly linked to various types of
cancers and does not seem to play an important role in
neuronal signalling [15–17].Nomenclature
The DLGAP protein family is known under several
different names. Initially DLGAP1 was named
Guanylate kinase associated protein (GKAP) since it
interacts with the guanylate kinase (GK) domain of
SAP90/PSD-95 [5]. Shortly after, three other similar
proteins were and the family of four proteins was
subsequently named as SAP90/PSD95-associatedle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Table with the DLGAP subtypes expressed in the brain i.e. DLGAP1–4 and the corresponding CNS diseases and affected
brain regions
DLGAP subtype CNS disease Brain region affected References
DLGAP1 Schizophrenia Nucleus accumbens [9]
Alzheimer’s disease Frontal cortex [114]
Major depressive disorder Hippocampus [115]
DLGAP2 Schizophrenia na* [99]
Fragile x mental retardation Hippocampus [116]
Post traumatic stress disorder Hippocampus [102]
Autism spectrum disease na* [10, 100, 101]
DLGAP3 Trichotillomania Striatum [11, 12]
Obsessive compulsive disorder Striatum [11, 13, 106]
Parkinson’s disease na* [117]
Schizophrenia na* [98]
DLGAP4 Cerebellar ataxia Cerebellum [14]
Bipolar disorder (indirectly linked) na* [118]
na* No proven affected brain region. DLGAP1 is thought to be involved in schizophrenia starting from nucleus accumbens, Alzheimer’s disease in frontal cortex
and major depressive disorder originating from hippocampus. DLGAP2 is linked to multiple diseases. First schizophrenia with no proven affected brain region,
second autism spectrum disease also with no proven affected brain region and finally fragile x mental retardation and post-traumatic stress disorder both
originating from the hippocampus. DLGAP3 is proven to be involved in both trichotillomania and OCD both starting in the striatum. DLGAP3 has also been linked
to Parkinson’s disease. Finally, DLGAP4 is proven to be involved in cerebellar ataxia coming from cerebellum and indirectly to bipolar disorder via the microRNA
miR-1908-5p. The relevant references are linked in the fourth column, respectively
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still referred to as GKAP in the literature. PSD-95 is
also named Discs large scaffold protein 4 abbreviated
DLG4. Therefore, the SAPAP family proteins were
named discs large homolog associated protein
(DLGAP) 1–4. PSD-95 will in this work be referred
to as DLG4 and GKAP/SAPAP1–4 will be referred to
as DLGAP1–4.
DLGAP chromosomal localisation, protein homology and
conservation
Four DLGAP proteins are found in the human brain,
which are all encoded from a different locus. This
section contains an overview of the chromosomal
locations and mRNA transcript variants of DLGAP
genes in human. The DLGAP proteins have a high
sequential homology that we will review in detail
along with the conservation of the DLGAP family in
mammals and vertebrates.
Chromosomal localisation and mRNA transcripts
The DLGAP1–4 genes are located on 4 different
chromosomes. DLGAP1 is located on the short arm
of chromosome 18 within the band 11.31 (18p11.31)
and has 9 human transcript variants spanning from
2253 nucleotides to 6628 nucleotides (see Fig. 1a).
DLGAP2 is located on the short arm of chromosome
8, in the band 23.3 (8p23.3). Two transcript variants
have been identified for DLGAP2 having only one
exon difference. Transcript variant 1 has 12 exonsand transcript variant 2 has 11 exons (see Fig. 1a).
DLGAP3 is located on chromosome 1 in the band
34.3 on the short arm (1p34.3). Only one human
DLGAP3 transcript has been identified so far (see
Fig. 1a). The DLGAP4 gene is situated on the long
arm of chromosome 20 within the band 11.23
(20q11.23). Three transcript variants with varying
lengths from 3044 nucleotides to 5080 nucleotides
have been found in human (see Fig. 1a).
DLGAP protein homology
The many mRNA transcripts of DLGAP1–4 encode
DLGAP proteins with various lengths and domains (see
Fig. 2a). The pairwise homology between the DLGAP
proteins differ by 26 to 48%. DLGAP1 compared to
DLGAP2 show the highest homology and DLGAP3
compared to DLGAP4 show the lowest homology (see
Fig. 1b). DLGAP1–4 have 3 domains, a 14 amino acids
repeat domain, a dynein light chain (DLC) domain and a
GKAP homology (GH1) domain (see section 4.1).
Especially the GH1 domain by which the DLGAP
proteins are characterized, shows a high degree of
homology i.e. 61 to 75%. In addition, the last 40 residues
next to the C-terminal also show a high degree of
homology (see Fig. 1d).
Conservation
DLGAP1–4 are important proteins in the postsynaptic
density. They act as scaffold proteins and are involved in
signalling to and from glutamate receptors [19]. The
Fig. 1 a Pictogram of chromosome 18, 8, 1 and 20 and the four DLGAP1–4 loci, respectively. DLGAP1 is located on chromosome 18 and transcript
variants 1 to 9 are illustrated. DLGAP2 is found on chromosome 8 and has two transcript variants. The DLGAP3 gene is located on chromosome 1 and
has one transcript variant. DLGAP4 is located on chromosome 20 and has 3 transcript variants. b Heatmap showing the homology in percentage
between the longest isoform, isoform a, of DLGAP1–4 proteins respectively. The color key indicates the respective percentage to each colour. The
heatmap is created in RStudio v.0.99.484 with data from a multiple alignment made with clustal omega v.1.2.1. DLGAP1 isoform a: 977 amino acids
(NP_004737.2), DLGAP2 isoform a: 975 amino acids (NP_004736.2), DLGAP3 isoform a: 979 amino acids (NP_001073887.1) and DLGAP4 isoform a: 989
amino acids (NP_055717.2). c Phylogenetic tree of DLGAP1–4 protein conservation in following species; Homo sapiens (NP_004737.2, NP_004736.2,
NP_001073887.1, NP_001035951.1), Macaca mulatta (AFE64413.1, AFJ72104.1, AFE64177.1), Bos taurus (NP_001179558.1, DAA17363.1, NP_001179367.1,
AAI26739.1), Rattus norvegicus (NP_075235.3, NP_446353.2, NP_775161.2), Mus musculus (NP_808307.2, NP_766498.2, AAH57615.1, NP_001035953.1),
Pongo abelii (XP_009251088.1, NP_001127321.1), Xenopus tropicalis (NP_001123829.1, NP_001106458.1, XP_012827022.1) and Danio rerio
(NP_001189384.1, XP_009291347.1, NP_001038179.1, AAI33919.1). EV: Experimentally validated, CT: Conceptual Translation, P: Predicted from genomic
sequence. The phylogenetic tree is created in RStudio v.0.99.484 with data from a multiple alignment made with clustal omega v.1.2.1. d Figure of
multiple alignment of DLGAP1–4 GH1 domain and C-terminal. The sequence homology of the GH1 domain is 61 to 75% between DLGAP1 – DLGAP4.
The alignment and data is generated in clustal omega v.1.2.1 and visualized in CLC sequence viewer v.7.6
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likely because their function is highly essential. DLGAP
proteins have been experimentally found or predicted
from genomic sequences in Homo sapiens, Macacamulatta, Pongo abelii, Bos taurus, Rattus norvegicus,
Mus musculus and in the two vertebrates Danio rerio
and Xenopus tropicalis (see Fig. 1c). DLGAP1–4 was
originally found in rat [5, 18] but most research have
Fig. 2 a Pictogram of the DLGAP1–4 proteins with their respective domains. The DLGAP1–4 proteins have a 14 amino acid repeat domain (14-a.a.
repeats) with 0 to 5 repeats depending on the DLGAP isoform, a Dynein light chain (DLC) domain and a GKAP homology domain 1 (GH1). b
Illustration of how the four proteins interact. DLGAP binds via the C-terminal to the PDZ domain of SHANK. The 14-a.a. repeat domain of DLGAP binds
the GK domain of DLG. Homer binds with the EVH1 domain to the proline rich domain of SHANK
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the genes and proteins also are described best.
Domain overview and protein interaction
The DLGAP1–4 proteins contain several characterized
domains that enable them to interact with numerous
proteins in the PSD either directly or indirectly via other
scaffold proteins (see Fig. 2a-b). Some of these interact-
ing proteins, namely the DLG4 protein, the SHANK
family, the Homer family and the Stargazin protein will
also be reviewed here. These proteins all have domains
that have the capability to link DLGAP1–4 to the three
major glutamate receptors in the PSD, namely the
NMDA receptor, the AMPA receptor and the group I
mGluRs [1–3, 5, 20, 21].
The DLGAP family
As mentioned, the DLGAP proteins have three known
domains, a 14-a.a. repeat domain, a DLC domain and a
GH1 domain (see Fig. 2a). With the 14-a.a. domain
DLGAP proteins are capable of binding the GK domain
of DLG1, DLG2 and DLG4 [5, 22–24]. Depending on
the isoform, the 14-a.a. domain can be located in the
middle of the protein or near the N-terminal. For
example, in the long DLGAP1 isoforms (isoform a & c)
the repeats are located in the middle whereas in the
short isoforms (isoform b, d-i) the repeats are located
near the N-terminal. DLGAP1 has five 14-a.a. repeats
but some of the repeats are missing in the other DLGAP
proteins. For example, the long DLGAP4 isoform a lacks
the repeat number 3 and the short isoforms b and c do
not contain any of the 5 repeats (see Fig. 2a) [18]. This
diversity in repeats may contribute to their individual
function and binding affinity to DLG4 at the synapse.
The second domain, the DLC domain is located down-
stream of the repeats. This DLC domain interactsdirectly with DLC, a motor protein subunit found in the
dendrites and PSD [25]. The last domain, the GH1
domain, is found at the C-terminal. GH1 is composed of
4 alpha helices and display a high sequence homology
between the DLGAP proteins as previously mentioned
(see Figs. 1d and 2a & b). However, the role of the GH1
domain is still unknown [5, 6, 26].
Proteins interacting with the DLGAP family
The DLG family The DLG family is a group of proteins
also known as membrane-associated guanylate kinases
(MAGUKs). Three of these proteins; DLG1, DLG2
and DLG4 also known as SAP97, PSD-93 and PSD-
95, respectively, are known to interact directly with
DLGAP [22–24]. The DLG proteins are important
proteins in the PSD because they link other scaffold
proteins and signalling molecules either directly or in-
directly to the membrane bound ion channels. DLGs
are known to stabilize the glutamate receptors upon
binding and they may also trigger synaptic growth by
modulation of growth-related proteins in the PSD [4].
DLGs, like DLGAP proteins, are also involved in
synaptic scaling [4, 27–29], which is a process that is
associated with schizophrenia [30]. The link of DLG1,
DLG2 and DLG4 to schizophrenia has been well
documented [31–36]. Additionally, DLG4 has been
linked to ASD [37].
DLGs have three different types of domains where the
first type is the Postsynaptic density protein; Drosophila
disc large tumor suppressor; Zonula occludens-1 protein
(PDZ) domain. In addition, DLGs have a Src Homology
3 (SH3) domain and a GK domain. DLGs have 3 PDZ
domains (see Fig. 2b). The second PDZ domain binds
the C-terminal of NMDA receptors [1]. Downstream of
the PDZ domains, the SH3 domain is located, which has
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protein 150, AKAP150 [38]. Also, DLGs can create
intramolecular interactions by binding the SH3 domain
to the GK domain [39]. Most likely DLG proteins are
also able to dimerize via SH3:GK interactions. With its
GK domain DLGs interact directly with most DLGAP
proteins through the 14-a.a. repeat domain [5] (see
Fig. 2b). With the GK domain and the second PDZ
domain DLGs acts as scaffolds between the DLGAP
proteins and the NMDA receptors and AMPA receptors
via Stargazin (see section 4.2.4) [3].
The SHANK family DLGAP proteins bind a second
family of proteins, the SHANK proteins [2]. Most
SHANK proteins are highly expressed in the PSD
and they are important for the maturation of the
PSD. Overexpression of SHANK leads to earlier mat-
uration of the postsynapse by recruitment and inter-
action with other scaffold proteins. There are three
SHANK genes in humans that encode 3 SHANK
proteins (SHANK1–3). SHANK3 has been linked to
schizophrenia whereas SHANK1–3 have all been
linked to ASD [40].
SHANK proteins do not directly bind to glutamate re-
ceptors in the PSD but SHANK1–3 have the capability
to link the ionotropic glutamate receptors to the metab-
otropic glutamate receptors by dimerization and mo-
lecular interaction with other scaffold proteins.
Compared to DLGAP1–4 and DLG4, SHANK1–3 are
longer proteins and have more domains (see Fig. 2b).
Close to the N-terminal SHANK1–3 has a SHANK/Pro-
SAP (SPN) domain followed by 7 Ankyrin (Ank) repeats.
Like DLG4, SHANKs also have a SH3 domain and one
PDZ domain. Downstream of PDZ, a proline rich do-
main is found, which is followed by a sterile alpha motif,
SAM, domain close to the C-terminal. The SPN domain
is largely uncharacterized. However, two binding part-
ners have been reported for the Ank repeats, the protein
alpha-Fodrin [41] and the Sharpin protein [42]. Both
proteins bind to the cytoskeleton [43, 44]. Interestingly,
the long isoform of SHANK2 with the Ank repeats,
SHANK2E, seems not to be expressed in the PSD but
mostly in epithelial cells [45]. SHANK1–3 has one SH3
domain like DLG4. In SHANK1–3, this domain medi-
ates interaction with the PSD scaffold protein Densin-
180. Densin-180 can promote dendritic branching. This
feature is however negatively regulated when Densin-
180 interacts with SHANK proteins [46]. Close to the
SH3 domain, SHANK1–3 have a PDZ domain. The C-
terminal of DLGAP1–4 interacts directly with
SHANK1–3 via this domain [2] (see Fig. 2a & b). Hereby
SHANK1–3 are linked to the postsynaptic plasma mem-
brane via DLGAP1–4, PSD-95 and NMDA receptors.
Downstream close to the N-terminal SHANK1–3 have aSAM domain, which bind other SAM domains for
multimerization of SHANK1–3 proteins [47].
Multimerization of SHANK1–3 proteins can generate a
network in the PSD that link numerous proteins to the
postsynaptic receptors. This network also enables down-
stream signalling cascades from the postsynaptic glutam-
ate receptors in which DLGAP proteins are an
important element. Finally, SHANK1–3 also connects to
the Homer family, via the proline rich domain [20].
The Homer family The Homer family consists of 3
proteins (Homer1–3) with various isoforms encoded by
3 HOMER genes. The Homer proteins have a function
in neuronal development [48] and they play a central
role in the PSD because these proteins bind to group I
mGluRs and regulate the activity hereof [49, 50].
Homer1 has been linked to mental retardation
syndromes in Fragile X mental retardation patients and
in Fragile mental retardation 1 (FMR1) knockout mice
[51, 52]. Abnormal spine densities were found in the
FMR1 knockout mice, which support the importance for
Homer proteins in neuronal development and proper
PSD function.
Homer1–3 have two known domains. The first domain
is the highly conserved Ena/VASP Homology 1 (EVH1)
domain and the second domain is a coiled coil (CC) do-
main (see Fig. 2b). The EVH1 domain is located near the
N-terminal and with this domain Homer1–3 interacts
with the proline rich domain of SHANK1–3 [20]. In
addition Homer1–3 have the ability to interact with
group I mGluRs that also have a proline rich domain
[21]. DLGAP1–4 is not directly associated with
Homer1–3. However, Homer1–3 are interesting because
they connect DLGAP1–4 to group I mGluR via
SHANK1–3 (see Fig. 2b). Like DLG4 and SHANK1–3,
Homer1–3 also have the capability to dimerize. The CC
domain can bind other CC domains for homodimeriza-
tion [53].
Stargazin DLGAP proteins indirectly interact with Star-
gazin via DLG4, which is interesting because it couples
DLGAP proteins to the AMPA receptor. Stargazin is a tet-
raspanning transmembrane protein also known as calcium
channel, voltage-dependent, gamma subunit 2. Stargazin
shows structural resemblance to calcium channel, voltage-
dependent, gamma subunit 1, which is a subunit in
voltage gated calcium channels. Thus, it was first believed
to be a calcium channel subunit [54], Stargazin is not a
genuine subunit of calcium channels [55]. Stargazin is well
known from the stargazer mouse, a model of ataxia and
epilepsy where the Stargazin gene is deleted [56, 57].
Stargazin was found to interact with AMPA receptors and
regulate their synaptic targeting, surface trafficking and
trafficking to endosomes in ion channel scaling. This
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acts with the PDZ domain of DLG4 [3, 58–60]. Stargazin
also plays an important role in the function of AMPA re-
ceptors. Stargazin can modulate the biophysical properties
and channel gating of AMPA receptors [61–64].
Moreover, Stargazin can increase the efficacy of agonists
on AMPA receptors and it can also act to slow down
deactivation of AMPA receptors after glutamate binding
[62, 65, 66].DLGAP1–4 expression in the brain
DLGAP1–4 are expressed throughout the body but in
general they are expressed in much higher levels in the
brain [6]. DLGAP1–4 are mainly localized in the den-
drites and the postsynapse of excitatory synapses (see
Fig. 3) [18, 67, 68]. In the brain the expression of
DLGAPs is widespread and the different isoforms show
a somewhat different expression pattern. In situ
hybridization experiments on rat and mouse brain tissue
show that Dlgap1 mRNA is expressed in cortex, hippo-
campus, olfactory bulb, striatum, thalamus as well as in
both granule layer and Purkinje cells of cerebellum (see
Table 2) [6, 68]. The expression of Dlgap2 resembles
that of Dlgap1 with expression in cortex, hippocampus
and olfactory bulb. However, Dlgap2 is highly expressed
in the striatum and interestingly Dlgap2 is the only
Dlgap that is not expressed in the cerebellum and in the
thalamus [68]. Expression of Dlgap3 mRNA is observed
throughout the mouse brain including the cortex, thal-
amus, retina and olfactory bulb with high levels in the
hippocampus, striatum and granule cells of cerebellum
[68]. In cortex and cerebellum, the expression level ofFig. 3 DLGAPs are proteins of the postsynaptic density. The postsynaptic loca
a panDLGAP immunostaining. The excitatory postsynapses were visualized w
marker. Left scale bar, 20 μm; right scale bar, 3 μmDLGAP3 varies in the postnatal rat brain. Around
3 weeks after birth the expression level peaks [69]. There
are three transcript variants expressed from the DLGAP4
locus, which are all present in the brain. Transcript vari-
ant 1 however, is totally brain specific whereas transcript
variant 2 and 3 show tissue-wide expression [14]. In the
brain DLGAP4 shows high expression in the hippocam-
pus, striatum, thalamus, amygdala, substantia nigra and
in the Purkinje cells of cerebellum [14, 18, 68, 69].Functional role of DLGAP proteins
DLGAP proteins are involved in ion channel scaling at the
synapse
The DLGAP1 protein is enriched in the synapse
where it acts as a scaffold protein and contributes to
synaptic scaling [8]. Synaptic scaling, a form of
homeostatic synaptic plasticity, is a function of the
excitatory synapses to reset the neuronal firing rate to
“normal” levels. The firing rate is normalized by a
change in the postsynaptic response in every synapse
of a neuron. The change in postsynaptic response re-
sults from alterations in the activity of neurotransmit-
ter receptors like AMPA and NMDA receptors. For
example, NMDA receptor scaling is regulated via the
number of NMDA receptors at the synapse. The
number of NMDA receptors functions as a bidirec-
tional feedback mechanism. When the synapse is
inactive, NMDA receptors are transported from the
endoplasmic reticulum to the synapse. When the syn-
apse is active, synaptic NMDA receptors undergo
endocytosis and export of NMDA receptors from the
endoplasmic reticulum slows down [70].lization of DLGAPs in a cultured rat hippocampal neuron as revealed by
ith an antibody directed against PSD-95 and MAP-2 used as a dendritic
Table 2 The table shows where the DLGAP subtypes are
expressed in the brain (Brain region, second column)
DLGAP subtype Brain region Brain region References























In the third column the expression level for the specific brain region is
indicated. ↑; indicates high expression, M; indicates medium expression and ↓;
indicates low expression levels. In the fourth column relevant references
are linked
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receptors are supplemented by a turnover of proteins
in the PSD. The level of the scaffold protein DLG4,
which interacts with the cytoplasmic tail of NMDA
receptors (reviewed here: Sheng [71]) is reduced
during NMDA receptor activity. Reduction of DLG4
at synaptic sites is a result of ubiquitination and
proteasomal degradation [72, 73]. DLGAP proteins
appear to control the DLG4 degradation indirectly.
Upon dissociation of the DLGAP 14-a.a. domain from
the DLG4 GK domain, both DLGAP1 and DLG4 are
ubiquitinated and degraded [8, 74]. The DLG4-
DLGAP1 interaction is disrupted by phosphorylation
of DLGAP1, which is catalyzed by the Ca2+/calmodulin-
dependent protein kinase II alpha chain (αCaMKII).
αCaMKII is activated by influx of Ca2+ ions through the
NMDA receptors upon activation. The scaffold pro-
tein SHANK is also downregulated at the synapse as
a result of DLGAP1 phosphorylation [8]. The phos-
phorylation most likely disrupts the interaction of theC-terminal of DLGAP1 with the PDZ domain of
SHANK (see Fig. 4a) [75].
During synaptic inactivation DLGAP1, DLG4 and
SHANK are, like the NMDA receptors, accumulating
at the synapse again. DLGAP1 seems to be the linker
in this accumulation. However, DLGAP1, DLG4 and
SHANK are equally dependent on each other for
accumulation (see Fig. 4a) [76]. It is believed that the
scaffold proteins and NMDA receptors have a fast
turnover with a short lifespan at the synapse [77].
DLGAP1 turnover seems to be important in synap-
tic scaling mediated by influx of Ca2+ ions through
the NMDA receptors but it also plays a role in
AMPA receptor scaling. It is known that DLG4 indir-
ectly binds to AMPA receptors through Stargazin [3].
Further, DLGAP proteins interact with DLG4 as
described above and phosphorylation of DLG4 by
protein kinase A (PKA) leads to removal of AMPA
receptors from the membrane by endocytosis [72].
Research has also shown, that loss of DLGAP3 causes
silencing of AMPA receptors at the postsynapse [78].
In addition, overexpression of mutant DLGAP1 in
hippocampal neurons eliminate homeostatic regulation
of AMPA receptor surface expression [8].
DLGAP proteins clearly have a central role in ion
channel synaptic scaling including both NMDARs and
AMPARs. This function of DLGAPs appears to be
achieved in concert with DLG4, SHANK, αCaMKII and
possibly Stargazin.
DLGAP proteins control metabotropic glutamate receptor
group I induced synaptic scaling
The group I metabotropic glutamate receptors
(mGluRs) belong to a class of receptors in the
mGluR family that is involved in synaptic scaling
[79]. mGluRs are G-protein coupled receptors
(GPCR) that bind glutamate. Upon glutamate
binding of group I mGluRs, phospholipase C (PLC)
hydrolyses phospholipids in the membrane.
Subsequently inositol 1,4,5-triphosphate (IP3) and
diacyl glycerol (DAG) are released, which can lead to
activation of protein kinase C (PKC) and increased
intracellular levels of Ca2+ (see Fig. 4b). The group I
mGluR family includes two receptors, namely
mGluR1 and mGluR5. Group I mGluRs can modu-
late NMDA and AMPA receptor activity and induce
synaptic scaling upon activation. The scaffold protein
Homer seems to be required for group I mGluR
induced synaptic scaling [79] and for the crosstalk
between group I mGluRs and the NMDA and AMPA
receptors [80]. The crosstalk is likely mediated
through a DLG4-DLGAP-SHANK-Homer complex
[21]. Homer binds to the C-terminal of group I
mGluR [81] and the coupling of Homer to the group
Fig. 4 a Proposed model of the states in ion channel mediated synaptic scaling. In the active synapse calcium influx through the NMDA receptor
activates CaMKII that utilizes ATP to phosphorylate DLGAP that causes dissociation from DLG4 and SHANK and prones them for ubiquitination (Ub).
Subsequently, DLGAP, DLG4 and SHANK are degraded, which results in endocytosis of the AMPA and NMDA receptors. During synaptic inactivation
the scaffold proteins DLGAP, DLG4 and SHANK accumulate together with the AMPA and NMDA receptors that are incorporated in the membrane. b
Proposed model of mGluR mediated synaptic scaling displayed as an equilibrium between the active and the inactive synapse. The synaptic scaling is
initiated by activation of mGluR1/5 by glutamate followed by PLC-mediated membrane release of DAG. The release of DAG leads to activation of PKC
and release of intracellular Ca2+. The increase in calcium ions activates CaMKII that phosphorylates DLGAP and Homer. After phosphorylation DLGAP
dissociates from DLG4 and SHANK, and Homer dissociates from mGluR1/5 and SHANK. DLGAP, DLG4, Homer and SHANK are then ubiquitinated (Ub)
and degraded. With no intracellular bound scaffold proteins, NMDA receptors and AMPA receptors are internalised and removed from the synapse. In
the inactive synapse after activation the scaffold proteins DLGAP, DLG4, Homer and SHANK accumulate together with AMPA receptors and NMDA
receptors that are incorporated into the membrane. c Working model of endocannabinoid-mediated synaptic depression that is initiated by glutamate
stimulation of mGluR1/5 that leads to PLC-mediated release of DAG. Then, DAG is converted to the endocannabinoid 2-AG that is transported to the
synaptic cleft where it binds to the endocannabinoid receptor CB1R. After activation of CB1R, glutamate release from the presynapse to the synaptic
cleft is halted, which leads to the depression. Presence of DLGAP in the PSD inhibits this endocannabinoid synaptic depression most likely via a
DLGAP-SHANK-Homer- mGluR1/5
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is, like for DLGAP1, also controlled by phosphoryl-
ation catalysed by CaMKII [82]. In addition to
Homer, DLGAPs are also believed to play an import-
ant role in group I mGluR induced synaptic scaling.
This is due to the essential binding to both DLG4
and SHANK, and research show that loss of
DLGAP2 causes significant downregulation of Homer
and AMPA receptors [83]. DLGAP’s role in group I
mGluR synaptic scaling is probably not much differ-
ent from its role in ion channel scaling. DLGAPs are
likely phosphorylated by CaMKII upon group I
mGluR activation. Phosphorylation of DLGAP and
Homer leads to degradation or removal of DLGAP,
Homer, DLG4 and SHANK from the PSD. Upondegradation or removal of scaffold proteins, the
NMDA and AMPA receptors are unstable and subse-
quently removed from the membrane via endocytosis
(see Fig. 4b).
The role of endocannabinoids in synaptic depression is
guarded by DLGAP
The group I mGluRs can regulate synaptic plasticity
via release of intracellular Ca2+ as described above.
Another way group I mGluRs can regulate synaptic
plasticity is through endocannabinoid mediated
synaptic depression. Endocannabinoids are a class of
lipids that are synthesized from membrane-bound
phospholipids. The synthesis occurs after activation of
group I mGluRs where the phospholipids are
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mechanisms. For example, DAG that is released from
the membrane by PLC after group I mGluR activation
is converted to the endocannabinoid 2-Arachidonoyl
glycerol (2-AG). After synthesis the endocannabinoids
are transported into the synaptic cleft and to the
presynapse where the endocannabinoid receptor 1
(CB1R) is located. The CB1R is a GPCR and upon
endocannabinoid binding, downstream signalling is
initiated. One downstream signalling cascade results
in inhibition of neurotransmitter release from the
presynapse (see Fig. 4c) [84]. The scaffold protein
Homer1 that binds group I mGluRs seems to play a
role in the endocannabinoid signalling [85]. Homer1
expression regulates endocannabonoid production as
a result of mGluR stimulation. Besides Homer1,
DLGAP3 also regulates endocannabinoid mediated
synaptic depression. In Dlgap3 knockout mice,
endocannabinoid-dependent synaptic depression is
increased in the striatum in a mGluR dependent
manner [7]. This indicates that the presence of
DLGAP proteins in the PSD activates or promotes
synaptic transmission by inhibiting mGluR-mediated
endocannabinoid signalling. The scaffold protein
SHANK binds both DLGAP and Homer why
DLGAP3 most likely controls endocannabinoid signal-
ling through a DLGAP3-SHANK-Homer-group I
mGluR complex (see Fig. 4c).
DLGAP proteins in neurological and psychiatric disorders
The DLGAP proteins are expressed in the postsy-
napse and interact with several proteins involved in
the function and maintenance of the NMDA, AMPA
and group I mGluR glutamate receptors. DLGAPs
play an important role in the PSD and even small
changes in expression of DLGAPs could have severe
consequences in the signalling within the PSD. It is
therefore not surprising that all DLGAPs have been
linked to various psychiatric and neurological disor-
ders including schizophrenia, OCD and cerebellar
ataxia (see Table 1) [9, 11, 14].
Schizophrenia and DLGAPs
Schizophrenia is a widespread, complex mental dis-
order that is characterized by symptoms like delu-
sions, hallucinations and abnormal social behaviour. It
affects approximately 1% of the population worldwide
[86]. Schizophrenia has a high degree of heritability
however, a large fraction of patients do not have a
family history which can be explained by sporadic
mutations [87, 88].
Schizophrenia is functionally associated with the
NMDA receptors [89, 90]. One hypothesis behind the
NMDA receptor influence in schizophrenia is explainedby altered glutamate signalling as a result of reduced or
increased incorporation of NMDA receptors in the post-
synaptic membrane [91, 92]. As explained in section 6,
DLGAPs influence NMDA receptor synaptic scaling via
DLG4 and both DLG4 and DLGAP1 have been linked to
schizophrenia. The DLG family members, DLG1 and
DLG2, which also interact with DLGAPs and NMDA
receptors [93–95] have been linked to schizophrenia as
well [35–37].
Analysis of brain samples from post mortem
schizophrenic patients revealed that the level of
DLG4 was downregulated in anterior cingulate
cortex [33]. Another study demonstrated increased
expression of DLGAP1 in the nucleus accumbens
[9]. Moreover, the expression level of DLG1 and
DLG2 was also found to be significantly skewed in a
schizophrenia rat model and in schizophrenic
patients [32, 96–98]. The deregulation of DLGs and
DLGAP1 in these patients could be an indication of
malfunction of NMDA receptors. Especially the
NMDA subunit, GluN2A shows altered expression in
schizophrenic patients [91, 92]. The schizophrenia-
related upregulation of DLGAP1 expression could be
the result of a feedback mechanism where the
neurons are trying to re-establish the normal
function and signalling of the GluN2A containing
NMDA receptor.
After the discovery of the potential role of DLGAP1
in schizophrenia, related gene family members have
also been analysed extensively in genetic studies.
Multiple single nucleotide variations (SNVs) have
been reported in DLGAP2 and DLGAP3 genes in
schizophrenia patient cohorts [99, 100]. In DLGAP3
two SNVs were identified in the C-terminal, one of
which was located in a domain which is believed to
affect the post-translational modification of the
DLGAP3 protein. It was speculated that all the
DLGAP3 SNVs would impact the interaction with
protein kinases and thereby the function of DLGAP3
[99]. No functional studies have yet been conducted
on DLGAP2 and DLGAP3 in relation to schizophre-
nia. DLGAP2 and DLGAP3 have only been linked to
schizophrenia in genetic screens. Yet, genetic changes
in DLGAP2 and DLGAP3 are considered as suscepti-
bility factors for schizophrenia [99, 100].Other brain disorders and DLGAPs
The DLGAPs have been linked to a number of brain
disorders in addition to schizophrenia. DLGAP2 was
identified as a candidate gene for ASD where patients
display impaired social interaction and communication
skills in addition to having stereotyped interests and
behaviours [10, 101, 102].
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and post-traumatic stress disorder (PTSD), which is ob-
served as a result of a traumatic experience. In a rat model
of PTSD, a change in methylation and in expression of
Dlgap2 was shown in the hippocampus [103]. In individ-
uals with PTSD the hippocampus is known to be smaller
and less activated [104–106]. Moreover, Dlgap2 knockout
(Dlgap2−/−) mice showed deficits in learning, abnormal
social behaviour and intense aggressive behaviour, which
is characteristic for both ASD and PTSD [83].
Biochemical studies revealed that specific subunits in
the AMPA and NMDA receptors, the scaffold protein
Homer1 and αCaMKII were significantly downregulated
in the Dlgap2−/− mice resulting in disruption of both
synaptic transmission and synaptic structure [83].
DLGAP3 has been associated with OCD, which arises
from anomalous signalling in the striatum and develops
into a phenotype where the patients need to check or
perform certain things repeatedly. Dlgap3 knockout
(Dlgap3−/−) mice showed increased self-grooming bouts
compared to wild type mice, which resulted in lesions in
their head and neck. In addition, the Dlgap3−/− mice
exhibited increased anxiety-like behaviour, which is also
characteristic for OCD [11].
Since Dlgap3−/− mice showed OCD-like symptoms,
patients with the grooming disorder, trichotillomania
(hair-pulling disorder) and OCD were genotyped for
SNVs in the DLGAP3 locus [12]. An association was
found between variations in the DLGAP3 gene and
trichotillomania, which appeared to be familial.
However, a coherence between variants in the DLGAP3
gene and OCD was not obvious [12]. Other studies have
nonetheless linked genetic variants in DLGAP3 to
OCD-like symptoms. In patients with OCD and tricho-
tillomania, multiple and rare missense mutations were
found in the DLGAP3 gene [107].
The fourth DLGAP gene, DLGAP4, has been related
to cerebellar ataxia. Our group had discovered a
familial translocation between chromosome 8 and
20 t(8:20) segregating with early-onset cerebellar
ataxia [108]. This translocation resulted in symptoms
including ataxia, clumsiness, impaired hand coordin-
ation and tremors. The translocation disrupted the
DLGAP4 locus and separated the promoter and the
first exon from the rest in transcript variant 1, which
is brain-specific. In addition, the translocation
disrupted the DLGAP4 promoter associated CpG
island which lead to epigenetic changes and increased
expression of the DLGAP4 transcript variant 2 [14].
The misregulation of DLGAP4 could very likely lead to
altered surface expression of both ionoptropic and me-
tabotropic glutamate receptors in the PSD. Deregulation
of glutamate receptor turnover, could potentially be
followed by a faulted glutamate signalling from thepresynapse to the postsynapse leading to the reported
phenotype. In fact, both loss of AMPA receptors and
loss of group I mGluR signalling have previously been
associated with cerebellar ataxia [109–111].
Conclusions
In this review we have focused on members 1 to 4 of the
DLGAP protein family with regard to their function in
the brain and involvement in neurological diseases. The
DLGAP proteins have multiple domains and act as
scaffold proteins in the PSD where they enable crosstalk
between metabotropic and ionotropic glutamate recep-
tors via other scaffold proteins including DLG4, SHANK
and Homer [1–5, 21, 47, 49, 50, 58–60]. DLGAPs are
believed to control synaptic scaling as a result of NMDA
receptor, AMPA receptor and group I mGluR activation
[3, 5, 7, 8, 58–60]. Undoubtedly further research on this
topic would be of great value to decipher the role of the
individual DLGAP proteins and the interplay between
the DLGAP proteins in neuronal synapses. To under-
stand the implication of DLGAPs in neurological disor-
ders will be of great importance. Multiple studies have
been conducted on DLGAPs in relation to schizophrenia
[37, 86, 112–114]. Specifically, there is heavy literature
on involvement of DLGAP1 in schizophrenia and suggest-
ing DLGAP2 as a candidate gene for ASD [10, 100, 101]
and PTSD [83, 102]. It is likely that mutations in DLGAP2
could lead to the symptoms seen in ASD and PTSD pa-
tients. The data convincingly depicts the DLGAP3 gene as
a disease gene for both OCD and trichotillomania [11–13,
106]. In contrast to DLGAP1–3, the general literature on
DLGAP4 is very limited. DLGAP4 is proposed as a
candidate gene for cerebellar ataxia [14] but DLGAP4 was
never investigated in studies of the Stargazer mouse, a
mouse model of cerebellar ataxia [3, 54, 56]. More re-
search and data is expected in the coming years to clarify
the role of DLGAP1, 2, 3 and 4 in synaptic plasticity and
their involvement in schizophrenia and neurological
diseases.
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